Hunneman, Donald H.

[["dc.bibliographiccitation.firstpage","220"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","MEDICAL AND PEDIATRIC ONCOLOGY"],["dc.bibliographiccitation.lastpage","223"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Hero, Barbara"],["dc.contributor.author","Hunneman, Donald H."],["dc.contributor.author","Gahr, M."],["dc.contributor.author","Berthold, F."],["dc.date.accessioned","2018-11-07T09:36:29Z"],["dc.date.available","2018-11-07T09:36:29Z"],["dc.date.issued","2001"],["dc.description.abstract","Background. The early biological response has been proved an excellent predictor in acute lymphoblastic leukemia and nephroblastoma. We asked whether catecholamine metabolites, mIBG scan, and bone marrow evaluation might be relevant response markers in disseminated neuroblastoma. Procedure. Three hundred sixty-seven unselected stage 4 neuroblastoma patients treated according the German cooperative trial NB90 were entered into the study. Catecholamine plasma and urine levels were centrally determined by gas chromatography/ mass spectrometry. Bone marrow cytology and mIBG scans were evaluated by local investigators. Results. Ar diagnosis, mIBG scan was positive in 306 patients (92%), borderline in seven patients (2%), and negative in 19 patients (6%). Bone marrow aspirates were cytologically positive in 292 patients (84%) and negative in 57 patients (16%). Plasma catecholamine levels were elevated in 79% (206 of 260 patients.), urinary levers in 92% (307 of 338 patients). The outcome of patients with normalized mIBG scan after four courses of chemotherapy [5 year EFS (event free survival) 0.22 +/- 0.071 was not superior to the outcome of patients with still abnormal uptake (5 year EFS 0.30 +/- 0.05). The event free survival of patients with still positive bone marrow aspirates after four courses (0.16 +/- 0.06) was inferior to the EFS of patients with negative bone marrow aspirates (0.26 +/- 0.04, P = 0.0054). Urinary catecholamine normalization after four cycles of chemotherapy (5 year EFS 0.35 +/- 0.06 Versus 0.26 +/- 0.10) had no influence on outcome, whereas plasma catecholamine normalization after the first (5 year EFS 0.40 +/- 0.09 versus 0.14 +/- 0.07, P = 0.0364) or the fourth cycle (5 year EFS 0.35 +/- 0.06 versus 0.26 +/- 0.10, P = 0.0242) indicated a better outcome. Conclusions. These data show that serial plasma catecholamine levels and bone marrow aspirates in the course of the disease are useful toots in predicting outcome. Med. Pediatr. Oncol. 36:220-223, 2001. (C) 2001 Wiley-Liss, Inc."],["dc.identifier.doi","10.1002/1096-911X(20010101)36:1<220::AID-MPO1053>3.0.CO;2-6"],["dc.identifier.isi","000166167300053"],["dc.identifier.pmid","11464889"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32629"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.publisher.place","New york"],["dc.relation.conference","Advances in Neuroblastoma Research Meeting"],["dc.relation.eventlocation","BATH, ENGLAND"],["dc.relation.issn","0098-1532"],["dc.title","Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1899"],["dc.bibliographiccitation.issue","13"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","1903"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Simon, T."],["dc.contributor.author","Hero, Barbara"],["dc.contributor.author","Hunneman, Donald H."],["dc.contributor.author","Berthold, F."],["dc.date.accessioned","2018-11-07T10:36:27Z"],["dc.date.available","2018-11-07T10:36:27Z"],["dc.date.issued","2003"],["dc.description.abstract","The value of the tumour markers vanillylmandelic acid (VMA) and homovanillic acid (HVA) in urine (u) and serum (s), neurone-specific enolase (NSE). and lactate dehydrogenase (LDH) in the early prediction of relapse/progression in neuroblastoma is not known. We analysed the data of neuroblastoma patients who had successfully completed first-line treatment and had laboratory results available from their initial diagnosis and from relapse/progression (n = 196). Patients' overall survival from relapse or progression was 21.5 +/- 4.2% (mean standard deviation). At diagnosis, we found abnormal results in 75% for VMA and/or HVA (s), 92% for VMA and/or HVA (u), 90% for NSE, and 81% for LDH. We found a lower incidence of abnormal results at relapse or progression,with 40% for VMA and/or HVA (s), 54% for HVA and/or VMA (u), 61% for NSE, and 48% for LDH. Sensitivity of markers was higher for metastatic compared with local recurrence. NSE was the best, being able to detect 42% of the localised relapses. 77% of the combined local/metastatic relapses, and 69% of the metastatic recurrences. Relapse or progression in neuroblastoma cannot be detected reliably by monitoring tumour markers alone. Therefore, follow-up of neuroblastoma patients must include clinical assessment and imaging studies. (C) 2003 Elsevier Ltd. All rights reserved."],["dc.identifier.doi","10.1016/S0959-8049(03)00376-9"],["dc.identifier.isi","000185327400013"],["dc.identifier.pmid","12932669"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45328"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0959-8049"],["dc.title","Tumour markers are poor predictors for relapse or progression in neuroblastoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]